AveXis (AVXS) Price Target Raised to $152.00
AVXS has been the subject of several other reports. Royal Bank of Canada reaffirmed a hold rating and set a $92.00 price objective on shares of AveXis in a report on Thursday, November 2nd. Canaccord Genuity began coverage on AveXis in a report on Thursday, October 26th. They set a hold rating and a $110.00 price objective for the company. Zacks Investment Research cut AveXis from a buy rating to a hold rating in a report on Monday, October 30th. BidaskClub raised AveXis from a sell rating to a hold rating in a report on Thursday, December 21st. Finally, Chardan Capital reaffirmed a buy rating and set a $135.00 price objective on shares of AveXis in a report on Friday, January 5th. Three equities research analysts have rated the stock with a sell rating, four have given a hold rating and fifteen have assigned a buy rating to the stock. AveXis presently has an average rating of Buy and an average target price of $116.95.
AveXis (NASDAQ AVXS) opened at $111.90 on Friday. The stock has a market capitalization of $4,020.00 and a price-to-earnings ratio of -20.05. AveXis has a 1-year low of $53.94 and a 1-year high of $128.00.
Large investors have recently made changes to their positions in the company. Strs Ohio purchased a new stake in shares of AveXis in the third quarter valued at $116,000. Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of AveXis by 57.5% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,241 shares of the company’s stock valued at $137,000 after purchasing an additional 453 shares during the period. Ameritas Investment Partners Inc. grew its position in shares of AveXis by 331.0% in the second quarter. Ameritas Investment Partners Inc. now owns 2,112 shares of the company’s stock valued at $174,000 after purchasing an additional 1,622 shares during the period. Cubist Systematic Strategies LLC grew its position in shares of AveXis by 688.6% in the third quarter. Cubist Systematic Strategies LLC now owns 1,806 shares of the company’s stock valued at $175,000 after purchasing an additional 1,577 shares during the period. Finally, Teacher Retirement System of Texas purchased a new stake in shares of AveXis in the third quarter valued at $200,000. 81.52% of the stock is owned by institutional investors and hedge funds.
AveXis Company Profile
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.